(Circulation. 2000;102:260.)
© 2000 American Heart Association, Inc.
Basic Science Reports |
Widening of the Excitable Gap During Pharmacological Cardioversion of Atrial Fibrillation in the Goat
Effects of Cibenzoline, Hydroquinidine, Flecainide, and d-Sotalol
From the Department of Physiology, Maastricht University, Maastricht, Netherlands.
Correspondence to Prof Dr M.A. Allessie, Department of Physiology, Maastricht University, PO Box 616, 6200 MD Maastricht, Netherlands.
Background—Previous studies suggest that the antifibrillatory action of class I and III drugs is due to prolongation of the atrial wavelength. The aim of the present study was to directly evaluate the electrophysiological action of antifibrillatory drugs in a goat model of chronic atrial fibrillation (AF).
Methods and Results—Six goats were instrumented with multiple atrial electrodes, and sustained AF was induced by electrical remodeling. During sustained AF, the effects of intravenous infusion of cibenzoline, hydroquinidine, flecainide, and d-sotalol on AF cycle length (AFCL), refractory period (RPAF), conduction velocity (CVAF), pathlength (PLAF), wavelength (WLAF), temporal (AFCL-RPAF), and spatial (PLAF-WLAF) excitable gap were studied. The RPAF was measured by determining the earliest moment at which single stimuli could capture the fibrillating atria. CVAF was measured during regional entrainment of AF. Contrary to our expectation, cardioversion of AF could not be attributed to prolongation of WLAF. Hydroquinidine and d-sotalol did not affect WLAF significantly, whereas cibenzoline and flecainide even shortened WLAF by 18% and 36%, respectively. PLAF was increased by hydroquinidine and d-sotalol by 30%, whereas cibenzoline and flecainide did not prolong PLAF. The only parameter that correlated consistently with cardioversion of AF was a widening of the temporal excitable gap (cibenzoline 176%, hydroquinidine 105%, flecainide 86%, d-sotalol 88%).
Conclusions—Pharmacological cardioversion of AF cannot be explained by prolongation of WLAF. An alternative explanation for the antifibrillatory effect of class I and III drugs may be a widening of the temporal excitable gap.
Key Words: fibrillation • drugs • conduction • waves
This article has been cited by other articles:
 |
|
 |
|
  J. W. Cheng Vernakalant in the Management of Atrial Fibrillation Ann. Pharmacother., April 1, 2008; 42(4): 533 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Blaauw, U. Schotten, A. van Hunnik, H.R. Neuberger, and M.A. Allessie Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat Cardiovasc Res, July 1, 2007; 75(1): 89 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rivard, H. Sinno, A. Shiroshita-Takeshita, G. Schram, T.-K. Leung, and S. Nattel The pharmacological response of ischemia-related atrial fibrillation in dogs: Evidence for substrate-specific efficacy Cardiovasc Res, April 1, 2007; 74(1): 104 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bollmann, D. Husser, L. Mainardi, F. Lombardi, P. Langley, A. Murray, J. J. Rieta, J. Millet, S. B. Olsson, M. Stridh, et al. Analysis of surface electrocardiograms in atrial fibrillation: techniques, research, and clinical applications. Europace, November 1, 2006; 8(11): 911 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gulizia, S. Mangiameli, S. Orazi, G. Chiaranda, G. Boriani, G. Piccione, N. DiGiovanni, A. Colletti, C. Puntrello, G. Butera, et al. Randomized comparison between Ramp and Burst+ atrial antitachycardia pacing therapies in patients suffering from sinus node disease and atrial fibrillation and implanted with a DDDRP device Europace, July 1, 2006; 8(7): 465 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lofberg, I. Jacobson, and L. Carlsson Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro Europace, July 1, 2006; 8(7): 549 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Qu and J. N. Weiss Effects of Na+ and K+ channel blockade on vulnerability to and termination of fibrillation in simulated normal cardiac tissue Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1692 - H1701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Duytschaever, Y. Blaauw, and M. Allessie Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs Cardiovasc Res, July 1, 2005; 67(1): 69 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kneller*, J. Kalifa*, R. Zou, A. V. Zaitsev, M. Warren, O. Berenfeld, E. J. Vigmond, L. J. Leon, S. Nattel, and J. Jalife Mechanisms of Atrial Fibrillation Termination by Pure Sodium Channel Blockade in an Ionically-Realistic Mathematical Model Circ. Res., March 18, 2005; 96(5): e35 - e47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-R. Neuberger, U. Schotten, S. Verheule, S. Eijsbouts, Y. Blaauw, A. van Hunnik, and M. Allessie Development of a Substrate of Atrial Fibrillation During Chronic Atrioventricular Block in the Goat Circulation, January 4, 2005; 111(1): 30 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Comtois, J. Kneller, and S. Nattel Of circles and spirals: Bridging the gap between the leading circle and spiral wave concepts of cardiac reentry Europace, January 1, 2005; 7(s2): S10 - S20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Reisinger, E. Gatterer, W. Lang, T. Vanicek, G. Eisserer, T. Bachleitner, C. Niemeth, F. Aicher, W. Grander, G. Heinze, et al. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset Eur. Heart J., August 1, 2004; 25(15): 1318 - 1324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. KLEBER and Y. RUDY Basic Mechanisms of Cardiac Impulse Propagation and Associated Arrhythmias Physiol Rev, April 1, 2004; 84(2): 431 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ashihara, T. Namba, T. Ikeda, M. Ito, K. Nakazawa, and N. Trayanova Mechanisms of Myocardial Capture and Temporal Excitable Gap During Spiral Wave Reentry in a Bidomain Model Circulation, February 24, 2004; 109(7): 920 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ausma, H. M.W. van der Velden, M.-H. Lenders, E. P. van Ankeren, H. J. Jongsma, F. C.S. Ramaekers, M. Borgers, and M. A. Allessie Reverse Structural and Gap-Junctional Remodeling After Prolonged Atrial Fibrillation in the Goat Circulation, April 22, 2003; 107(15): 2051 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Zaitsev, P. K. Guha, F. Sarmast, A. Kolli, O. Berenfeld, A. M. Pertsov, J. R. de Groot, R. Coronel, and J. Jalife Wavebreak Formation During Ventricular Fibrillation in the Isolated, Regionally Ischemic Pig Heart Circ. Res., March 21, 2003; 92(5): 546 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kawase, T. Ikeda, K. Nakazawa, T. Ashihara, T. Namba, T. Kubota, K. Sugi, and H. Hirai Widening of the Excitable Gap and Enlargement of the Core of Reentry During Atrial Fibrillation With a Pure Sodium Channel Blocker in Canine Atria Circulation, February 18, 2003; 107(6): 905 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-F. Tse and C.-P. Lau Electrophysiologic actions of dl-sotalolin patients with persistent atrial fibrillation J. Am. Coll. Cardiol., December 18, 2002; 40(12): 2150 - 2155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Chorro, J. Guerrero, A. Ferrero, A. Tormos, L. Mainar, J. Millet, J. Canoves, J. C. Porres, J. Sanchis, V. Lopez-Merino, et al. Effects of acute reduction of temperature on ventricular fibrillation activation patterns Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2331 - H2340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Saksena, A. Prakash, P. Ziegler, J. D. Hummel, P. Friedman, V. J. Plumb, D. G. Wyse, E. Johnson, S. Fitts, R. Mehra, et al. Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing and antiarrhythmic drug therapy J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1140 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ohara, Z. Qu, M.-H. Lee, K. Ohara, C. Omichi, W. J. Mandel, P.-S. Chen, and H. S. Karagueuzian Increased vulnerability to inducible atrial fibrillation caused by partial cellular uncoupling with heptanol Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H1116 - H1122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Huang, J. L. Skinner, J. M. Rogers, W. M. Smith, W. L. Holman, and R. E. Ideker The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogs J. Am. Coll. Cardiol., July 17, 2002; 40(2): 375 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F Bosch and S. Nattel Cellular electrophysiology of atrial fibrillation Cardiovasc Res, May 1, 2002; 54(2): 259 - 269. [Full Text] [PDF]
|
|
|
|
|
|
S. Nattel Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc Res, May 1, 2002; 54(2): 347 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. Cosio and E. Delpon New Antiarrhythmic Drugs for Atrial Flutter and Atrial Fibrillation: A Conceptual Breakthrough at Last? Circulation, January 22, 2002; 105(3): 276 - 278. [Full Text] [PDF]
|
|
|
|
|
|
Members of the Sicilian Gambit New Approaches to Antiarrhythmic Therapy, Part I: Emerging Therapeutic Applications of the Cell Biology of Cardiac Arrhythmias Circulation, December 4, 2001; 104(23): 2865 - 2873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Members of the Sicilian Gambit New approaches to antiarrhythmic therapy; emerging therapeutic applications of the cell biology of cardiac arrhythmias Eur. Heart J., December 1, 2001; 22(23): 2148 - 2163. [Abstract] [PDF]
|
|
|
|
|
|
Members of the Sicilian Gambit New approaches to antiarrhythmic therapy: emerging therapeutic applications of the cell biology of cardiac arrhythmias Cardiovasc Res, December 1, 2001; 52(3): 345 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Disertori, L. Padeletti, M. Santini, P. Dini, M. Gasparini, G. Inama, M. Botto, G. Boriani, A. Capucci, R. Ricci, et al. Antitachycardia pacing therapies to terminate atrial tachyarrhythmias: the AT500 Italian Registry Eur. Heart J. Suppl., November 1, 2001; 3(suppl_P): P16 - P24. [Abstract] [PDF]
|
|
|
|
|
|
R. Ricci, C. Pignalberil, M. Disertori, A. Capucci, L. Padeletti, G. Botto, G. Boriani, F. Miraglia, T. de Santo, and M. Santini Antitachycardia pacing therapy to treat spontaneous atrial tachyarrhythmias: the 7250 dual defibrillator Italian Registry Eur. Heart J. Suppl., November 1, 2001; 3(suppl_P): P25 - P32. [Abstract] [PDF]
|
|
|
|
|
|
H.J.G.M. Crijns, T. van Noord, and I.C. van Gelder Recurrence of atrial fibrillation and the need for new definitions Eur. Heart J., October 1, 2001; 22(19): 1769 - 1771. [PDF]
|
|
|
|
|
|
M. Duytschaever, F. Mast, M. Killian, Y. Blaauw, M. Wijffels, and M. Allessie Methods for Determining the Refractory Period and Excitable Gap During Persistent Atrial Fibrillation in the Goat Circulation, August 21, 2001; 104(8): 957 - 962. [Abstract] [Full Text] [PDF]
|
|